Loading company…
Pin Therapeutics develops drugs designed to break down disease-causing proteins.
Founded in 2017 and based in Seongnam, South Korea, Pin Therapeutics develops targeted protein degradation drugs using UPS technology. Its programs include PROTAC and Molecular Glue Degrader approaches for pathogenic proteins associated with cancer. In February 2022, the company raised KRW 20 billion in series B funding from DSC Investment, KB Investment, Korea Investment Partners, and other investors to advance its research.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in